Clinical Updates and Cost Management Strategies in Treating Idiopathic Pulmonary Fibrosis

Clinical Updates and Cost Management Strategies in Treating Idiopathic Pulmonary Fibrosis is organized by Pharmacy Times Continuing Education (PTCE). 

Release Date: June 4, 2019
Expiration Date: June 4, 2020

Target Audience: 
Specialty Pharmacists and Managed Care Professionals.

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) 

Program Description:
Clinical management of idiopathic pulmonary fibrosis (IPF) is complex. Patients have a poor prognosis, with estimated life expectancies ranging from 3 to 5 years. Evolving knowledge of the pathogenesis of IPF has shown that the disease is linked to a dysregulated wound-healing cascade and fibroproliferation, which has allowed for the development of medications such as nintedanib and pirfenidone with different mechanisms to slow disease progression. As additional data become available, specialty pharmacists must be able recognize the strengths and limitations of new and emerging therapies to make cost-effective and clinically appropriate treatment decisions. Additionally, pharmacists can improve medication adherence by educating patients and caregivers about drug administration and handling, adverse effects, and the potential for drug interactions.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Identify evidence-based treatment plans for IPF
• Examine recent efficacy and safety data in IPF treatment
• Explain the use of cost-effectiveness data to develop IPF management plans

Additional details will be posted as soon as they are available.